Early research (Phase 1)Study completedNCT05079750What this trial is testingA New Vaccine Against Two Types of EbolaWho this might be right forEbola University of Oxford 26
Early research (Phase 1)Study completedNCT02374385What this trial is testingPhase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus VaccineWho this might be right forEbola Viruses Dalhousie University 40
Post-approval studies (Phase 4)Study completedNCT03072030What this trial is testingInternational Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-CombiWho this might be right forEbola Virus DiseasePrevention Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 2,000
Early research (Phase 1)Study completedNCT04906629What this trial is testingINO-4201 as Booster in Healthy VSV-ZEBOV VaccineesWho this might be right forEbola Virus Disease University of Geneva, Switzerland 46
Large-scale testing (Phase 3)UnknownNCT04152486What this trial is testingEffectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCWho this might be right forEbola Virus Disease London School of Hygiene and Tropical Medicine 20,426
Early research (Phase 1)Study completedNCT02564575What this trial is testingEvaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsWho this might be right forHemorrhagic Fever, Ebola National Institute of Allergy and Infectious Diseases (NIAID) 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06803342What this trial is testingA Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsWho this might be right forEbola Sudan Virus Disease Albert B. Sabin Vaccine Institute 200
Large-scale testing (Phase 3)Ended earlyNCT02661464What this trial is testingLong-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-FiloWho this might be right forHemorrhagic Fever, Ebola Janssen Vaccines & Prevention B.V. 677
Post-approval studies (Phase 4)UnknownNCT06587503What this trial is testingSafety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster DosesWho this might be right forEbola Virus DiseaseCOVID-19 University of Birmingham 72
Early research (Phase 1)Study completedNCT00374309What this trial is testingExperimental Vaccine for Prevention of Ebola Virus InfectionWho this might be right forEbola Hemorrhagic FeverEbola Virus DiseaseEbola Virus Vaccines+2 more National Institute of Allergy and Infectious Diseases (NIAID) 48
Testing effectiveness (Phase 2)Study completedNCT04711356What this trial is testingAd26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)Who this might be right forEbola Virus Disease London School of Hygiene and Tropical Medicine 50
Early research (Phase 1)Study completedNCT04723602What this trial is testingEvaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy AdultsWho this might be right forEbola Virus DiseaseMarburg Virus Disease Albert B. Sabin Vaccine Institute 32
Early research (Phase 1)Study completedNCT03478891What this trial is testingSafety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy AdultsWho this might be right forHealthy Adult Immune Responses to Vaccine National Institute of Allergy and Infectious Diseases (NIAID) 19
Testing effectiveness (Phase 2)Study completedNCT03333538What this trial is testingRandomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-LyoWho this might be right forHealthy Volunteers Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 220
Testing effectiveness (Phase 2)Study completedNCT06036602What this trial is testingMonovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy AdultsWho this might be right forEbola Sudan Virus Disease Albert B. Sabin Vaccine Institute 125
Testing effectiveness (Phase 2)Study completedNCT03031912What this trial is testingAfrican-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-EbolaWho this might be right forEbola Canadian Immunization Research Network 251
Early research (Phase 1)Study completedNCT02313077What this trial is testingA Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy ParticipantsWho this might be right forHealthy Crucell Holland BV 87
Early research (Phase 1)Study completedNCT02464670What this trial is testingOpen-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersWho this might be right forEbola Vaccine Inovio Pharmaceuticals 240
Early research (Phase 1)Study completedNCT02283099What this trial is testingPhase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)Who this might be right forHemorrhagic Fever, Ebola Universitätsklinikum Hamburg-Eppendorf 30
Testing effectiveness (Phase 2)Study completedNCT02289027What this trial is testingA Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in SwitzerlandWho this might be right forEbola Vaccines Centre Hospitalier Universitaire Vaudois 120